Clinical Trials in Wodonga, Australia
1 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 3
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Germ Cell Tumor
University of Sydney500 enrolled28 locationsNCT02582697